1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Lombard Medical, Inc.

Lombard Medical, Inc.

EVARF
Lombard Medical, Inc.US flagOther OTC
0.00
USD
- -
- -
2,795.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
1.57
0.69
0.62
0.91
0.85
- -
0.61
Basic EPS, GAAP
-3.97
-1.47
-1.71
-2.39
-2.13
- -
-1.54
Free Cash Flow per Basic Share
-4.11
-1.35
-1.93
-2.48
-1.97
- -
-1.27
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-10.94
-9.66
-13.24
-12.82
- -
-12.81
Tangible Book Value per Share
- -
0.35
3.89
4.09
0.29
- -
-0.94
Basic Weighted Avg Shares
4
9
11
15
18
- -
20
Sales/Revenue/Turnover
6
6
7
13
15
12
12
Operating Margin (%)
-285.31
-211.92
-287.84
-272.22
-259.98
-232.98
-232.98
Depreciation Expense
- -
- -
1
1
2
2
2
Net Income, GAAP
-16
-13
-19
-35
-38
-31
-31
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-251.89
-213.15
-275.92
-261.75
-250.13
-255.03
-255.03
Working Capital
- -
2
43
59
36
24
24
LT Debt
- -
- -
3
3
23
30
30
Total Equity
- -
7
49
65
43
14
14
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
ST Debt
1
3
4
LT Borrowings
22
23
30
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
28
Market Capitalization
21
19
12

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
Total Current Assets
29
25
34
Cash, Cash Equivalents & STI
13
10
21
Accounts Receivable, Net
5
5
3
Inventories
9
9
7
Total Current Liabilities
8
11
10
Payables & Accruals
6
7
5
ST Debt
1
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-67.59%
Free Cash Flow
- -
17.46%
-27.36%
Net Income, GAAP
- -
19.81%
-17.91%
Sales/Revenue/Turnover
- -
18.79%
-19.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
2
2
4
5
13
2015
3
5
4
3
15
2016
3
4
3
2
12

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.43
-0.76
-0.52
-0.51
-2.39
2015
-0.59
-0.51
-0.45
-0.58
-2.13
2016
-0.38
-0.42
-0.37
-0.37
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Kurt Lemvigh
Full Time Employees
113
Sector
Healthcare
Industry
Medical - Devices
Address
4 Trident Park Didcot OX United Kingdom OX11 7HJ
IPO Date
Apr 25, 2014
Website
lombardmedical.com
Similar Companies
Quipt Home Medical Corp. (QIPT.V)
Intuitive Surgical, Inc. (ISRG)
GPX Medical AB (publ) (GPXMED.ST)
iRhythm Technologies, Inc. (IRTC)
3-D Matrix, Ltd. (7777.T)
Fischer Medical Ventures Ltd. (FISCHER.NS)
Business
Lombard Medical, Inc. Lombard Medical, Inc. (EVARF) is a United Kingdom-based medical device company that develops, manufactures, and markets endovascular stent-grafts for the minimally invasive repair of aortic aneurysms and related vascular diseases. The company offers a comprehensive portfolio of products including its proprietary Aorfix stent-graft, designed for abdominal aortic aneurysms with challenging neck angles up to 90 degrees; Altura stent-graft, an ultra-low-profile system for standard abdominal aortic aneurysm anatomy; and Meridian stent-graft, a 14F fenestrated device for complex fenestrated endovascular aortic repair (FEVAR). In partnership with MicroPort Endovastec, Lombard Medical provides additional innovative solutions such as the low-profile Minos AAA stent-graft; Hercules TAA stent-graft; Castor branched thoracic stent-graft with unibody design to preserve the left subclavian artery and reduce endoleak risks; and Hector triple branched thoracic stent-graft featuring integrated and pre-cannulated branches. These products target clinicians treating aortic pathologies including abdominal, thoracic, and branched aneurysms, with operations spanning Europe, the United States, Japan, Greece, Cyprus, Italy, Switzerland, and other international markets. Founded in 1994 and headquartered in Didcot, Oxfordshire, the company maintains a focused strategy on endovascular solutions for vascular disease. Recent developments include the first-in-world relining procedure using the Meridian FEVAR system in Greece approximately three months ago, marking its application in complex revision cases; first-in-Europe implantation of the MicroPort Endovastec Hector thoracic stent-graft at Zurich University Hospital in Switzerland seven months ago; multiple first-in-region procedures with the Castor thoracic stent-graft in Italy, Cyprus, and Greece over the past year; and ongoing clinical milestones such as the first MicroPort Endovastec Minos abdominal stent-graft discussions at major symposia like CX Symposium five months ago, alongside workshops demonstrating Hercules for physician-modified procedures. Lombard Medical operates as part of the MicroPort family following the 2018 acquisition by MicroPort Endovastec, which expanded its product breadth, manufacturing efficiency, and global commercialization in key regions including Europe, Latin America, Japan, and emerging markets.

Company News

APIChatGPT

  • defenseworld.net

    Penumbra (NYSE:PEN) & Lombard Medical (OTCMKTS:EVARF) Head-To-Head Survey